Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Average Recommendation of “Hold” by Analysts

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have been assigned an average recommendation of “Hold” from the seven analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $9.50.

Several equities research analysts recently commented on RXRX shares. JPMorgan Chase & Co. raised Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $10.00 to $11.00 in a report on Wednesday, December 17th. UBS Group set a $11.00 price objective on Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Wednesday, October 8th. Morgan Stanley set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Thursday, September 11th.

Recursion Pharmaceuticals Stock Performance

RXRX stock opened at $4.36 on Wednesday. The company has a 50-day simple moving average of $4.90 and a 200 day simple moving average of $5.13. The company has a market capitalization of $2.27 billion, a P/E ratio of -2.42 and a beta of 0.94. The company has a quick ratio of 4.60, a current ratio of 4.60 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals has a fifty-two week low of $3.79 and a fifty-two week high of $12.36.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.02. The company had revenue of $5.18 million for the quarter, compared to the consensus estimate of $19.36 million. Recursion Pharmaceuticals had a negative net margin of 1,637.81% and a negative return on equity of 72.74%. Recursion Pharmaceuticals’s revenue was down 80.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.34) EPS. Sell-side analysts predict that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Blake Borgeson sold 220,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $4.37, for a total transaction of $961,400.00. Following the completion of the sale, the director directly owned 6,869,863 shares in the company, valued at approximately $30,021,301.31. This trade represents a 3.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 8.43% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Clear Creek Financial Management LLC grew its holdings in shares of Recursion Pharmaceuticals by 10.0% in the 2nd quarter. Clear Creek Financial Management LLC now owns 23,442 shares of the company’s stock worth $119,000 after acquiring an additional 2,127 shares during the last quarter. TD Waterhouse Canada Inc. lifted its holdings in shares of Recursion Pharmaceuticals by 64.1% during the second quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock valued at $29,000 after purchasing an additional 2,200 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Recursion Pharmaceuticals by 16.8% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,439 shares of the company’s stock valued at $78,000 after purchasing an additional 2,219 shares during the period. Xponance Inc. increased its stake in Recursion Pharmaceuticals by 8.0% in the 3rd quarter. Xponance Inc. now owns 30,020 shares of the company’s stock worth $146,000 after purchasing an additional 2,221 shares in the last quarter. Finally, Main Management ETF Advisors LLC raised its holdings in Recursion Pharmaceuticals by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 142,914 shares of the company’s stock worth $723,000 after buying an additional 2,328 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.